On May 2, 2024, Karius®, Inc. (Karius), a world leader in genomic diagnostics for infectious disease, announced the successful completion of a $100 million Series C financing. Khosla Ventures, along with new investors 5AM Ventures and Gilde Healthcare, co-led the round. New investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others also participated. Wilson Sonsini Goodrich & Rosati advised Karius on IP matters related to the transaction.

Proceeds from the financing will expand access to Karius Test®, an infectious disease diagnostic test that employs genomic analysis and artificial intelligence to identify over 1,000 pathogens from a single blood sample, to meet increasing demand from healthcare providers. The investment will also bolster research into wider health implications of the company's microbial cell-free DNA technology.

The Wilson Sonsini team that advised Karius in IP matters related to the transaction includes Kimberly Stopak, William Barrett, Vern Norviel, Karl Hudspith, Nicholas Tiee, Laci Adolfo, and Irene Kasumba.

For more information, please see Karius' news release. Additional coverage can be found on Medical Device Network and Fierce Biotech.